A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 27 150 KRW 2.84% Market Closed
Market Cap: 1.3T KRW
Have any thoughts about
ABL Bio Inc?
Write Note

ABL Bio Inc
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ABL Bio Inc
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
A
ABL Bio Inc
KOSDAQ:298380
Short-Term Debt
â‚©0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Short-Term Debt
â‚©1.6T
CAGR 3-Years
47%
CAGR 5-Years
41%
CAGR 10-Years
19%
SK Bioscience Co Ltd
KRX:302440
Short-Term Debt
â‚©0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Short-Term Debt
â‚©0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Short-Term Debt
â‚©250m
CAGR 3-Years
-74%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Short-Term Debt
â‚©5B
CAGR 3-Years
21%
CAGR 5-Years
12%
CAGR 10-Years
N/A
No Stocks Found

ABL Bio Inc
Glance View

Market Cap
1.3T KRW
Industry
Biotechnology

ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.

Intrinsic Value
8 401.38 KRW
Overvaluation 69%
Intrinsic Value
Price
A

See Also

What is ABL Bio Inc's Short-Term Debt?
Short-Term Debt
0 KRW

Based on the financial report for Jun 30, 2024, ABL Bio Inc's Short-Term Debt amounts to 0 KRW.

Back to Top